Literature DB >> 29475019

Diastolic blood pressure is a potentially modifiable risk factor for preeclampsia in women with pre-existing diabetes.

Sidse Kjærhus Nørgaard1, Marianne Jenlev Vestgaard2, Isabella Lindegaard Jørgensen3, Björg Ásbjörnsdóttir2, Lene Ringholm4, Harold David McIntyre5, Peter Damm6, Elisabeth Reinhardt Mathiesen2.   

Abstract

AIMS: To identify early clinical, modifiable risk factors for preeclampsia present at first antenatal visit and assess the prevalence of pregnancy-related hypertensive disorders in women with pre-existing diabetes treated with tight glycemic and blood pressure (BP) control.
METHODS: A population-based cohort study of 494 women with pre-existing diabetes (307 and 187 women with type 1 and type 2 diabetes, respectively), included at their first antenatal visit from 2012 to 2016. The prevalence of chronic hypertension (without diabetic nephropathy or microalbuminuria), gestational hypertension and preeclampsia was recorded. Diabetic microangiopathy included presence of nephropathy, microalbuminuria and/or retinopathy. Treatment target was BP <135/85 mmHg.
RESULTS: HbA1c was 6.9 ± 2.4% (50 ± 12 mmol/mol) at first antenatal visit and 6.0 ± 0.6% (43 ± 6 mmol/mol) before delivery with no differences between women with type 1 and type 2 diabetes. At the first antenatal visit, the prevalence of microalbuminuria was 6% (6% vs. 6%), nephropathy 2% (1% vs. 2%) and chronic hypertension 6% (3% vs. 10%, p = 0.03). Gestational hypertension developed in 8% (9% vs. 6%) and preeclampsia developed in 8% (9% vs. 7%). Presence of diabetic microangiopathy (adjusted odds ratio (OR) 4.35 (confidence interval 2.12-8.93)) and diastolic BP (adjusted OR 1.72 per 10 mmHg (1.05-2.82)) at the first antenatal visit were independent risk factors for preeclampsia.
CONCLUSIONS: At the first antenatal visit, diastolic BP was the only independent, potentially modifiable risk factor for preeclampsia in women with pre-existing diabetes in the context of tight glycemic and BP control. One out of four women had hypertensive disorders during pregnancy.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Blood pressure; Pre-existing diabetes; Preeclampsia; Pregnancy; Prevalence; Risk factors

Mesh:

Substances:

Year:  2018        PMID: 29475019     DOI: 10.1016/j.diabres.2018.02.014

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  10 in total

1.  Clinical and Genetic Characteristics of Preeclampsia.

Authors:  O V Golovchenko; M Y Abramova; V S Orlova; I V Batlutskaya; I N Sorokina
Journal:  Arch Razi Inst       Date:  2022-02-28

2.  Implementing a community-level intervention to control hypertensive disorders in pregnancy using village health workers: lessons learned.

Authors:  Olukolade George Shobo; Anselm Okoro; Magdalene Okolo; Peter Longtoe; Isaac Omale; Endurance Ofiemu; Jennifer Anyanti
Journal:  Implement Sci Commun       Date:  2020-10-02

3.  Improving preeclampsia risk prediction by modeling pregnancy trajectories from routinely collected electronic medical record data.

Authors:  Shilong Li; Zichen Wang; Luciana A Vieira; Amanda B Zheutlin; Boshu Ru; Emilio Schadt; Pei Wang; Alan B Copperman; Joanne L Stone; Susan J Gross; Yu-Han Kao; Yan Kwan Lau; Siobhan M Dolan; Eric E Schadt; Li Li
Journal:  NPJ Digit Med       Date:  2022-06-06

4.  White coat hypertension in early pregnancy in women with pre-existing diabetes: prevalence and pregnancy outcomes.

Authors:  Marianne Vestgaard; Björg Ásbjörnsdóttir; Lene Ringholm; Lise Lotte T Andersen; Dorte M Jensen; Peter Damm; Elisabeth R Mathiesen
Journal:  Diabetologia       Date:  2019-10-18       Impact factor: 10.122

Review 5.  Improving pregnancy outcomes in women with diabetes mellitus: modern management.

Authors:  Lene Ringholm; Peter Damm; Elisabeth R Mathiesen
Journal:  Nat Rev Endocrinol       Date:  2019-07       Impact factor: 43.330

6.  CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial.

Authors:  Sidse Kjærhus Nørgaard; Elisabeth Reinhardt Mathiesen; Kirsten Nørgaard; Tine Dalsgaard Clausen; Peter Damm; Lene Ringholm
Journal:  BMJ Open       Date:  2021-04-09       Impact factor: 2.692

7.  Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: A systematic review and meta-analysis.

Authors:  Sophie Relph; Trusha Patel; Louisa Delaney; Soha Sobhy; Shakila Thangaratinam
Journal:  PLoS Med       Date:  2021-11-22       Impact factor: 11.069

8.  Complex Management of Nephrotic Syndrome and Kidney Failure during Pregnancy in a Type 1 Diabetes Patient: A Challenging Case.

Authors:  Leo Drapeau; Mathilde Beaumier; Julie Esbelin; François Comoz; Lucile Figueres; Giorgina Barbara Piccoli; Delphine Kervella
Journal:  J Clin Med       Date:  2022-09-27       Impact factor: 4.964

9.  Visit-to-visit blood pressure variability and risk of adverse birth outcomes in pregnancies in East China.

Authors:  Jieyu Liu; Luoqi Yang; Haoyue Teng; Yingying Cao; Jiaxiang Wang; Bing Han; Linghua Tao; Bo Zhong; Fangfang Wang; Chengqi Xiao; Zhongxiao Wan; Jieyun Yin
Journal:  Hypertens Res       Date:  2020-09-07       Impact factor: 3.872

10.  Potentially modifiable risk factors of preterm delivery in women with type 1 and type 2 diabetes.

Authors:  Julie C Søholm; Marianne Vestgaard; Björg Ásbjörnsdóttir; Nicoline C Do; Berit W Pedersen; Lone Storgaard; Birgitte B Nielsen; Lene Ringholm; Peter Damm; Elisabeth R Mathiesen
Journal:  Diabetologia       Date:  2021-06-19       Impact factor: 10.122

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.